Beacon Biosignals Raises $97 Million Series B to Advance At-Home EEG Brain Health Platform
Key Insights
Beacon Biosignals (search) completed a $97 million Series B financing round, bringing total cumulative funding to over $132 million to advance brain (search) health diagnostics.
The company combines FDA-cleared wearable EEG technology with advanced AI to capture real-world neural data for neurology (search), psychiatry (search), and sleep medicine (search) applications.
New investors including JSL Health (search), Palo Santo VC (search), and Samsung Next (search) joined the round to support scalable at-home EEG solutions for clinical trials and precision medicine.
Beacon Biosignals (search) announced the completion of an upsized Series B financing round totaling $97 million, extending the company's cumulative funding to over $132 million. The Boston-based neurotechnology company secured additional investment from new backers JSL Health (search), Palo Santo VC (search), Kicker Ventures, and Samsung Next (search), building on its previously announced $86 million Series B led by healthcare and technology investors including Innoviva, GV (Google Ventures) (search), S32, and General Catalyst (search).
The funding will accelerate Beacon's mission to transform brain (search) health through scalable, at-home electroencephalography (EEG) technology combined with advanced analytics, targeting applications in diagnostics, clinical trials, and precision medicine.
Platform Technology and Clinical Applications
Beacon Biosignals (search) has developed a platform that combines FDA-cleared wearable EEG technology with artificial intelligence to capture and analyze real-world neural data. The system enables objective measurement of brain (search) function across multiple therapeutic areas, including neurology (search), psychiatry (search), and sleep medicine (search).
The Beacon Platform provides clinicians and biopharmaceutical partners with quantitative measures of brain (search) function designed to accelerate research, improve diagnostic capabilities, and guide treatment development. This approach addresses the need for objective, scalable brain health assessment tools in clinical settings.
Strategic Positioning in Emerging Treatment Landscape
According to Daniel Goldberg, Managing Director at Palo Santo, Beacon is "uniquely positioned to unlock the potential of brain (search) data at scale." Goldberg noted that the company's combination of clinical-grade EEG and advanced analytics is "enabling a new era of discovery and precision in neuroscience."
The investment comes as novel therapeutic approaches, including psychedelic treatments, are reshaping the psychiatric disease (search) treatment landscape. Goldberg emphasized that platforms like Beacon's will be "critical for objectively measuring brain (search)-based outcomes and accelerating development" of these emerging therapies.
Leadership Perspective and Future Outlook
Jacob Donoghue, CEO of Beacon Biosignals (search), characterized the funding milestone as reflecting "strong momentum behind our vision to make brain (search) health measurable, scalable, and actionable." The executive expressed gratitude for investor support as the company works to "build the future of brain health."
The company's approach addresses the growing need for objective, quantifiable measures of brain (search) function that can be deployed outside traditional clinical settings, potentially expanding access to brain health monitoring and enabling more comprehensive data collection for therapeutic development.